期刊
CHEMICAL BIOLOGY & DRUG DESIGN
卷 83, 期 5, 页码 532-540出版社
WILEY
DOI: 10.1111/cbdd.12264
关键词
biocompatibility; blood cells; boron neutron capture therapy; erythrocytes; granulocytes; inflammation; megakaryocytes; platelets; thrombosis; toxicology
资金
- CARIPLO Foundation [2009-2440]
Boron neutron capture therapy (BNCT) is an anticancer treatment based on the accumulation in the tumor cells of B-10-containing molecules and subsequent irradiation with low-energy neutrons, which bring about the decay of B-10 to very toxic Li-7(3+) and He-4(2+) ions. The effectiveness of BNCT is limited by the low delivery and accumulation of the used B-10-containing compounds. Here, we report the development of folic acid-conjugated 4-amino-phenylboronate as a novel possible compound for the selective delivery of B-10 in BNCT. An extensive analysis about its biocompatibility to mature blood cells and platelet progenitors revealed that the compound markedly supports platelet aggregation, neutrophil oxidative burst, and inhibition of megakaryocyte development, while it does not have any manifest effect on red blood cells.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据